

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioners,

v.

JAZZ PHARMACEUTICALS IRELAND LTD.

Patent Owner

Case IPR2016-00002
Patent 8,772,306

**JAZZ PHARMACEUTICALS IRELAND LTD.'S EXHIBIT LIST AS OF
January 15, 2016 PURSUANT TO 37 C.F.R. § 42.63(e)**

EXHIBIT NO.	DESCRIPTION
Exhibit 2001	<p>Maitre M, The γ-Hydroxybutyrate Signalling System in Brain: Organization and Functional Implications, <i>Progress in Neurobiology</i>, Vol. 51, pp. 337-361 (1997) (“Maitre”)</p> <p>(Exhibit 1003 in Ranbaxy '306 patent IPR2016-00024)</p>
Exhibit 2002	<p>Knerr et al., Therapeutic Concepts in Succinate Semialdehyde Dehydrogenase (SSADH; ALDH5a1) Deficiency (γ-Hydroxybutyric Aciduria). Hypotheses Evolved From 25 Years of Patient Evaluation, Studies in <i>Aldh5a1</i>^{-/-} Mice and Characterization of γ-Hydroxybutyric Acid Pharmacology, <i>J. Inherit. Metab. Dis.</i>, Vol. 30, pp. 279-294 (2007)</p> <p>(Exhibit 1018 in Ranbaxy '306 patent IPR2016-00024)</p>
Exhibit 2003	<p>Bernasconi et al., Experimental Absence Seizures: Potential Role of γ-Hydroxybutyric Acid and GABA_B Receptors, <i>J. Neural Transm.</i>, Vol. 35, pp. 155-177 (1992)</p> <p>(Exhibit 1014 in Ranbaxy '306 patent IPR2016-00024)</p>
Exhibit 2004	<p>Löscher, W., Valproate: A Reappraisal of Its Pharmacodynamic Properties and Mechanisms of Action, <i>Progress in Neurobiol.</i>, Vol. 58, pp. 31-59 (1999)</p> <p>(Exhibit 1019 in Ranbaxy '306 patent IPR2016-00024)</p>
Exhibit 2005	<p>'306 Patent File History, Supplemental Amendment and Response filed November 13, 2013</p> <p>(Exhibit 1027 in Ranbaxy '306 patent IPR2016-00024)</p>
Exhibit 2006	<p>'306 Patent File History, Notice of Allowance</p>
Exhibit 2007	<p>Okun, M., GHB: An Important Pharmacologic and Clinical Update, <i>J. Pharm. Pharmaceut. Sci.</i>, Vol. 4(2), pp. 167-175 (2001) (“Okun”)</p> <p>(Exhibit 1004 in Ranbaxy '306 patent IPR2016-00024)</p>

EXHIBIT NO.	DESCRIPTION
Exhibit 2008	Van der Worp, H.B., Can Animal Models of Disease Reliably Inform Human Studies? <i>PLoS Medicine</i> , Vol. 7(3), pp. 1-8 (2010)
Exhibit 2009	Equetro® November 2012 Package Insert
Exhibit 2010	National Institute of Mental Health, Bipolar Disorder in Adults (2012)
Exhibit 2011	Morantz, C., Recommendations for Prescribing New Antiepileptic Drugs, <i>American Family Physician</i> , 70(6), pp. 1167-1168 (2004)
Exhibit 2012	Weisler, R., Carbamazepine extended-release capsules in bipolar disorder, <i>Neuropsychiatric Disease and Treatment</i> , 2(1), pp. 3-11 (2006)
Exhibit 2013	Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers (INX-189-005), clinicaltrials.gov (2012)
Exhibit 2014	DDI Study of Etravirine and GSK1265744, clinicaltrials.gov (2012)
Exhibit 2015	ERG, Examination of Clinical Trial Costs and Barriers for Drug Development (2014)
Exhibit 2016	Peterson, G.M., Valproate: a simple chemical with so much to offer, <i>J. of Clinical Pharmacy and Therapeutics</i> , 30, pp. 417-421 (2005)

Date: January 15, 2016

Respectfully submitted,

By: /F. Dominic Cerrito (Reg. No. 38,100)/

F. Dominic Cerrito (Reg. No. 38,100)

Evangeline Shih (Reg. No. 50,170)

Frank C. Calvosa (Reg. No. 69,064)

QUINN EMANUEL URQUHART &
SULLIVAN, LLP

51 Madison Avenue, 22nd Floor

New York, NY 10010

General Tel: (212) 849-7000

Fax: (212) 849-7100

Case IPR2016-00002
Patent 8,772,306
Patent Owner's Exhibit List

nickcerrito@quinnemanuel.com
evangelineshih@quinnemanuel.com
frankcalvosa@quinnemanuel.com

John V. Biernacki
Reg. No. 40,511
JONES DAY
North Point
901 Lakeside Avenue
Cleveland, Ohio 44114
General Tel: (216) 586-3939
Direct Tel: (216) 586-7747
Fax: (216) 579-0212
jvbiernacki@jonesday.com

*Attorneys for Jazz Pharmaceuticals
Ireland Ltd. and Jazz Pharmaceuticals,
Inc.*

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioners,

v.

JAZZ PHARMACEUTICALS IRELAND LTD.

Patent Owner

Case IPR2016-00002

Patent 8,772,306

CERTIFICATE OF SERVICE

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.